MENU
+Compare
CYDY
Stock ticker: OTC
AS OF
Aug 7 closing price
Price
$0.26
Change
-$0.01 (-3.70%)
Capitalization
327.95M

CYDY CytoDyn Inc. Forecast, Technical & Fundamental Analysis

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection... Show more

CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CYDY with price predictions
Aug 07, 2025

Momentum Indicator for CYDY turns negative, indicating new downward trend

CYDY saw its Momentum Indicator move below the 0 level on July 21, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CYDY turned negative on July 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYDY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CYDY entered a downward trend on July 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYDY advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

CYDY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.130). P/E Ratio (0.000) is within average values for comparable stocks, (57.859). CYDY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.470). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (276.117).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYDY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CYDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1111 Main Street
Phone
+1 360 980-8524
Employees
12
Web
https://www.cytodyn.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HCPIX88.63N/A
N/A
ProFunds UltraSector Health Care Inv
ASYLX15.66N/A
N/A
AB Select US Long/Short Advisor
GCINX15.12N/A
N/A
Green Century MSCI Intl Indx Indvl Inv
HCAFX44.48N/A
N/A
Hartford Capital Appreciation F
MCSSX39.17-0.34
-0.86%
NYLI WMC Enduring Capital Investor Class

CYDY and Stocks

Correlation & Price change

A.I.dvisor tells us that CYDY and LVTX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYDY and LVTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYDY
1D Price
Change %
CYDY100%
-2.59%
LVTX - CYDY
32%
Poorly correlated
N/A
AGNPF - CYDY
24%
Poorly correlated
N/A
HUMA - CYDY
21%
Poorly correlated
+11.76%
GNMSF - CYDY
14%
Poorly correlated
N/A
BMNDF - CYDY
12%
Poorly correlated
N/A
More